HAE · the NYSE · USD · Market cap $4.8B · 3,009 employees
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions.
FAIL · Does not pass the screen
106.60 USD
At the last full screen 2026-08-26
Screened 2026-08-26 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Haemonetics Corporation holds its Markup at $106.60. The statistical read favours the sellers, held for 118 days.
As held on the ledger · 2026-08-26
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 118 days
Price at the screen
$106.60
Valuation
51.50 trailing · 18.57 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.52
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
51.11%
Below 33%
Interest-bearing debt is 51.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
19.30%
Below 49%
Money owed to the company is 19.3% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. A 9.7% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Buy. The average target sits +1% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Blood Tech Firm Lacks Spark Despite Safety Margin
Picture a hospital running low on plasma, the quiet network of machines and software that keeps supplies moving. Haemonetics sits in that chain, selling automated collection systems across plasma, blood centres and hospital wards. Revenue edges up just 5 percent a year, margins sit at 7 percent and return on equity reaches only 12 percent. The shares trade at 13.8 times forward earnings with a 34 percent gap to our fair value, yet the opportunity rating stays at none.
We pass because the numbers do not add up to anything special. Growth stays modest, profitability thin and the moat unknown. Ten analysts call the stock a buy with an $88 median target, still below our calculated worth, but nothing here suggests the business can widen its lead or lift returns enough to justify a position.
Currency swings and hospital budget cycles add real volatility. Low margins leave little room if collection volumes slow or rivals gain ground. Ethical screen clears, yet the overall picture stays unconvincing. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HAE trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-31Markup · changed$106.60+36.9%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 36.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
2026-07-18Markup$78.20+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 9%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it buy, with a mean price target of $82.
2026-07-03Markup$78.20+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$78.20Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
